132 related articles for article (PubMed ID: 37731068)
1. Invasive fungal infection following venetoclax and posaconazole co-administration.
Reynolds G; Urbancic KF; Fong CY; Trubiano JA
Br J Haematol; 2023 Nov; 203(4):593-598. PubMed ID: 37731068
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: Clinical features, risk factors, and posaconazole profiles.
Hong JY; Kang CI; Yang J; Ko JH; Huh K; Cho SY; Chung DR; Jung CW; Peck KR
Med Mycol; 2023 Apr; 61(5):. PubMed ID: 37120735
[TBL] [Abstract][Full Text] [Related]
3. Rethinking the definition of 'less intensive' for venetoclax-combining regimens in acute myeloid leukaemia patients.
Borlenghi E; Roccaro AM; Cattaneo C
Br J Haematol; 2023 Nov; 203(4):504-506. PubMed ID: 37803499
[TBL] [Abstract][Full Text] [Related]
4. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study.
Copley MS; Waldron M; Athans V; Welch SC; Brizendine KD; Cober E; Siebenaller C
Int J Antimicrob Agents; 2020 Mar; 55(3):105886. PubMed ID: 31926286
[TBL] [Abstract][Full Text] [Related]
6. Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia.
White O; Kennedy E; Huckabee JB; Rogers E; LeBlanc TW; Dillon M; Li Z; Hanna D
J Oncol Pharm Pract; 2024 Apr; 30(3):527-534. PubMed ID: 37186784
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
Liebenstein TK; Widmer KM; Fallon MJ
J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
[TBL] [Abstract][Full Text] [Related]
8. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
10. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
[No Abstract] [Full Text] [Related]
11. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
12. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
13. Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study.
Chen X; Wang J; Wang S; Jin J; Li J; Gao S; Li J; Li J; Liu Q; Hu Y; Lin D; Sun Z; Yang J; Hu J; Wu X; Huang X; Shao Z; Deng Q; Wang C; Liu L; Chen H; Wang J; Wei X; Shen J; Zhang X; Wu D
Medicine (Baltimore); 2021 Jul; 100(30):e26772. PubMed ID: 34397725
[TBL] [Abstract][Full Text] [Related]
14. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
[TBL] [Abstract][Full Text] [Related]
15. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
Wasylyshyn A; Linder KA; Castillo CG; Zhou S; Kauffman CA; Miceli MH
Mycopathologia; 2020 Apr; 185(2):299-306. PubMed ID: 31939052
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
[TBL] [Abstract][Full Text] [Related]
17. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.
Korula A; Abraham A; Abubacker FN; Viswabandya A; Lakshmi KM; Abraham OC; Rupali P; Varghese GM; Michael JS; Srivastava A; Mathews V; George B
Mycoses; 2017 Oct; 60(10):686-691. PubMed ID: 28736936
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
Rausch CR; DiPippo AJ; Jiang Y; DiNardo CD; Kadia T; Maiti A; Montalban-Bravo G; Ravandi F; Kontoyiannis DP
Clin Infect Dis; 2022 Oct; 75(9):1503-1510. PubMed ID: 35325094
[TBL] [Abstract][Full Text] [Related]
19. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia.
Tu S; Zhang K; Wang N; Chu J; Yang L; Xie Z
Sci Rep; 2023 Nov; 13(1):18789. PubMed ID: 37914820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]